Skip to content
drillr.ai
Sign up

PCVX

Vaxcyte, Inc.

NASDAQ · Healthcare · Biotechnology · US

$63.68
+0.09%
Ask drillr

  • Oct 9, 2026, 20:54 UTC

    Vaxcyte, Inc. agreed to issue $575 million of 1.50% convertible senior notes due 2032, including a $75 million over-allotment option exercised in full.

  • Oct 5, 2026, 20:28 UTC

    Vaxcyte, Inc. commenced underwritten public offerings of $500 million of common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032.

    Source:

  • Oct 5, 2026, 14:23 UTC

    Vaxcyte shares spiked 57% after its lead vaccine candidate showed trial results positioning it against Pfizer and Merck.

    Source:

  • Oct 5, 2026, 13:30 UTC

    Vaxcyte shares surged 55%, the largest single-day gain in nearly four years.

    Source:

  • Oct 5, 2026, 10:00 UTC

    Vaxcyte reported positive topline data from the pivotal adult Phase 3 OPUS-1 trial of its 31-valent pneumococcal conjugate vaccine candidate VAX-31, which met all prespecified primary endpoints across age groups studied compared to Prevnar 20 and/or Capvaxive.

    Source:

  • Oct 4, 2026, 21:00 UTC

    Vaxcyte announced it will host a webcast and conference call on October 5, 2026 to present topline data from the OPUS-1 pivotal Phase 3 trial of its 31-valent pneumococcal conjugate vaccine candidate VAX-31.

    Source:

  • Sep 3, 2026, 20:43 UTC

    Vaxcyte, Inc. appointed Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer, effective September 3, 2026.

  • Aug 23, 2026, 08:10 UTC

    Deutsche Bank AG acquired a new minority stake in Vaxcyte, Inc., purchasing 258,338 shares valued at approximately $15.02 million, representing 0.18% ownership, as disclosed in an SEC filing.

    Source:

  • Aug 16, 2026, 19:45 UTC

    Baupost Group eliminated its entire 800,000-share stake in Vaxcyte during the June quarter, as disclosed in its 13F filing on August 13, 2026.

    Source:

  • Aug 5, 2026, 00:00 UTC

    Vaxcyte, Inc. reported a net loss of $284.3 million for Q2 2026, with diluted EPS of -$1.97.

  • Jun 23, 2026, 00:00 UTC

    Moncef Slaoui was appointed as a Class II director on the Board of Directors of Vaxcyte, Inc., effective June 17, 2026.

  • Jun 23, 2026, 00:00 UTC

    Jacks Lee retired from the Board of Directors of Vaxcyte, Inc., effective June 17, 2026.

  • Jun 2, 2026, 20:05 UTC

    Vaxcyte dosed the first participant in a Phase 1 study of its VAX-A1 vaccine candidate for Group A Streptococcus prevention.

    Source: